Roche is discontinuing its partnership with the Wilex subsidiary Heidelberg Pharma with respect to a collaboration in antibody-targeted amanitin conjugates (ATACs). The license agreement was signed in 2013 and expanded in October 2014.

Roche recently has increased the focus of its oncology research strategy on cancer immunotherapies and deprioritized other internal and external oncology research programs accordingly. Affected by this deprioritization are the collaborative research efforts with Heidelberg Pharma, which in recent years have progressed well, on schedule, and in a mutually satisfactory manner.